Jonah Feldman

Most patients with heavily pretreated chronic GVHD experienced clinical benefit with axatilimab, with the majority continuing treatment after approval.

Phase 3 results show that fecal microbiotherapy achieved a 62% GI response rate and a 54% 1-year survival in patients who had failed both corticosteroids and ruxolitinib.

In patients with high-grade uterine sarcoma who achieved disease control, cabozantinib did not prolong survival and had added toxicity.

FDA clears teclistamab plus daratumumab for early-relapse multiple myeloma, delivering striking PFS gains and scalable outpatient use.

A single-arm study of a BCMA CAR T-cell therapy after induction for newly diagnosed multiple myeloma led to 100% minimal residual disease negativity at 3 months.

A real-world analysis of patients receiving teclistamab prior to 2022 showed comparable outcomes to clinical trials and indicated adoption of proactive adverse event management.

Ozekibart, irinotecan, and temozolomide yielded a high response rate and maintained tolerability in patients with relapsed/refractory Ewing sarcoma.

In an interview, Paul G. Richardson, MD, gave an overview of the ways that CELMoDs are poised to impact the landscape of multiple myeloma treatment at various stages of disease treatment.

A 31-gene expression profile–based sentinel lymph node biopsy risk model, i31-SLNB, demonstrated a role in predicting lymph node positivity in T1b to T2a melanoma.

Fifty patients are enrolled to receive EBX-102-02 or placebo to address gut microbiome disruption associated with allogeneic hematopoietic cell transplant.

In this interview, Sagar Lonial, MD, discusses the EXCALIBER-RRMM trial design and the potential role of iberdomide in the evolving therapeutic landscape of multiple myeloma.

A validated analysis of nearly 22,000 patients receiving allogeneic hematopoietic cell transplant led to development of a risk calculator for acute graft-vs-host disease.

The addition of the CELMoD mezigdomide to carfilzomib and dexamethasone led to progression-free survival improvement in relapsed/refractory multiple myeloma.

The FDA granted approval of the combination of teclistamab and daratumumab for patients with 1-3 prior lines of therapy in myeloma.

In an interview, Vincent Ma, MD, discussed how ctDNA levels after the first cycle of immune checkpoint inhibitor in melanoma could shed light on clinical outcomes.

Adding nivolumab/ipilimumab to liver-directed melphalan improved outcomes in patients with metastatic uveal melanoma.

Erica Pimenta, MD, PhD, discussed the goals and key findings from her and her colleagues’ research into IGF-1 and GLP-1 signaling pathways in liposarcoma.

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for FDA approvals in multiple myeloma.

Tumor-infiltrating lymphocyte therapy yielded favorable results in a small cohort of patients with soft tissue sarcoma, leading to plans for a larger trial.

Experts discuss the SWOG S1512 trial of desmoplastic melanoma and the greater relevance of trials of immunotherapy in rare disease states.

The first patient was treated in a study of continuous subcutaneous administration of lenalidomide in multiple myeloma.

The NCCN guidelines now include the Merlin CP-GEP assay as part of shared decision-making for a sentinel lymph node biopsy in patients with melanoma.

Preclinical and early clinical data showed that a proteasome inhibitor could increase BCMA expression after failure of CAR T-cell therapy.

An overview of the FDA’s draft guidance on MRD as a clinical trial end point, with expert insight on what it means for drug development in multiple myeloma.

Circulating tumor DNA showed potential as a dynamic biomarker in assessing response to immune checkpoint inhibitors in melanoma.

The FDA accepted the new drug application for iberdomide based on minimal residual disease negativity benefit shown in the EXCALIBER-RRMM trial.

Cabozantinib plus temozolomide led to favorable short-term progression-free survival in a single-arm trial of patients with advanced leiomyosarcoma.

FDA accepts Ameluz PDT sNDA for superficial basal cell carcinoma, with strong phase 3 clearance data and a September 2026 decision deadline.

In an interview, Saad Z. Usmani, MD, MBA, discussed the significance of phase 1 outcomes of gintemetostat therapy for patients with heavily pretreated multiple myeloma.

Real-world data show over an 40% response rate for lifileucel TIL therapy, indicating that those treated earlier did better and fewer doses of IL-2 could be used effectively.